Plaque psoriasis is responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances continue to be made, including a better understanding of the long-term safety and efficacy of approved medications, as well as the introduction of new classes of medications. Join Steven Feldman, MD, PhD, as he reports on research results of these advances presented at the 2022 American Academy of Dermatology Meeting. Three studies presented as posters in the meeting will be described, along with expert comments on the clinical implications of the study results by Dr. Feldman and the principal investigator.
0.75 AMA PRA Category 1 CreditsTM
This activity was developed for dermatologists, dermatology advanced practice providers, and other clinicians who manage patients with moderate to severe plaque psoriasis.
This activity is supported by an educational grant from Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC and Arcutis Biotherapeutics, Inc.